Asciminib
$300.00
CAS No.: 1492952-76-7
Catalog No.: TQP0925
Purity: 95%
MF: C20H18ClF2N5O3
MW: 449.845
Storage: 2-8 degree Celsius
SMILES: ClC(OC1=CC=C(C=C1)NC(C1=CN=C(C(=C1)C1=CC=NN1)N1C[C@@H](CC1)O)=O)(F)F
Catalog No.: TQP0925
Purity: 95%
MF: C20H18ClF2N5O3
MW: 449.845
Storage: 2-8 degree Celsius
SMILES: ClC(OC1=CC=C(C=C1)NC(C1=CN=C(C(=C1)C1=CC=NN1)N1C[C@@H](CC1)O)=O)(F)F
CAS No.: 1492952-76-7; Asciminib. PROPERTIES: Asciminib is a white to off-white powder with a molecular formula of C29H26F3N5O2 and a molecular weight of 555.54 g/mol. It has a melting point around 175-180 C and exhibits limited water solubility (approximately 0.15 mg/mL). The compound is sensitive to photodegradation and requires storage at 2-8 C in amber glass containers. Safety measures include wearing protective eyewear and laboratory coats during handling to prevent skin contact. The substance is classified as a Category 2 eye damage hazard and Category 3 acute toxicity (oral). APPLICATIONS: Asciminib has been developed as a selective BCR-ABL1 inhibitor for treating chronic myeloid leukemia (CML). Its mechanism involves binding to the myristoyl pocket of the BCR-ABL1 kinase, as described in the Journal of Medicinal Chemistry. Clinical trials published in Blood have demonstrated its efficacy in patients with CML resistant to traditional tyrosine kinase inhibitors. Research in the New England Journal of Medicine has also explored its use in Philadelphia chromosome-positive acute lymphoblastic leukemia, showing promising response rates in combination therapies. Additionally, Asciminib has been investigated for its potential in overcoming tyrosine kinase inhibitor resistance through novel combination approaches, with studies in Leukemia suggesting enhanced efficacy when used with second-generation BCR-ABL1 inhibitors. Its unique binding mechanism has also been the subject of structural biology research focusing on kinase inhibitor design.
Reviews
Write Your Own Review